Escherichia coli Nissle 1917

Escherichia coli Nissle 1917 is a non-pathogenic probiotic strain that produces antimicrobial compounds like microcins and colicins to inhibit harmful bacteria. This strain strengthens intestinal barrier function through enhanced tight junction proteins and modulates immune responses via dendritic cell activation.

Origin & History

Escherichia coli Nissle 1917 is a non-pathogenic probiotic strain isolated by Dr. Alfred Nissle in 1917. It is recognized for its ability to colonize the human gut and promote health.

Historical & Cultural Context

Discovered during World War I, Escherichia coli Nissle 1917 has been used in Europe as a therapeutic probiotic for over a century, particularly in Germany.

Health Benefits

- Supports gut health by balancing intestinal flora, which enhances nutrient absorption and reduces digestive discomfort. - May prevent and treat gastrointestinal disorders by inhibiting the growth of harmful bacteria, reducing the risk of infections. - Enhances immune function by stimulating the production of protective antibodies, lowering the risk of infections. - Reduces inflammation by modulating cytokine production, which can alleviate symptoms of inflammatory bowel diseases. - Supports mental health by producing neurotransmitters like serotonin, which can improve mood and reduce anxiety. - Enhances skin health by maintaining a balanced gut microbiome, which is linked to reduced acne and eczema flare-ups. - Supports cardiovascular health by reducing cholesterol levels, as shown in studies where participants experienced a 10% reduction in LDL cholesterol.

How It Works

E. coli Nissle 1917 produces antimicrobial peptides including microcins H47 and M, along with colicins that directly inhibit pathogenic bacteria growth. The strain enhances intestinal barrier function by upregulating tight junction proteins claudin-1 and ZO-1, while stimulating dendritic cells to produce anti-inflammatory cytokine IL-10. It also competes with pathogens for iron through siderophore production and adhesion sites on intestinal epithelial cells.

Scientific Research

Escherichia coli Nissle 1917 has been extensively studied and is one of the most researched probiotic strains for treating gastrointestinal disorders, with numerous clinical trials supporting its efficacy.

Clinical Summary

Clinical trials demonstrate E. coli Nissle 1917's efficacy in maintaining ulcerative colitis remission, with studies showing comparable effectiveness to mesalamine in 327 patients over 12 months. A randomized controlled trial of 116 patients found significant reduction in IBS symptoms after 6 weeks of treatment. Meta-analyses indicate moderate evidence for preventing traveler's diarrhea and reducing antibiotic-associated diarrhea incidence. However, most studies are small-scale with heterogeneous populations, requiring larger trials for definitive therapeutic recommendations.

Nutritional Profile

- Contains live, beneficial bacteria. - Free from artificial ingredients. - Typically available in capsule or liquid form.

Preparation & Dosage

Recommended dosage is 1 to 2 capsules (around 10 billion CFU) per day. Consult a healthcare provider before use.

Synergy & Pairings

Lactobacillus rhamnosus, Bifidobacterium bifidum, Inulin

Safety & Interactions

E. coli Nissle 1917 is generally well-tolerated with mild gastrointestinal side effects like bloating or gas in <5% of users. The strain may theoretically interact with immunosuppressive medications by enhancing immune responses, though no specific drug interactions are documented. It should be avoided in severely immunocompromised patients, those with central venous catheters, or acute pancreatitis due to rare bacteremia risk. Pregnancy and breastfeeding safety data are limited, warranting caution in these populations.